Literature DB >> 9710685

Effects of vitamin E and HMG-CoA reductase inhibition on cholesteryl ester transfer protein and lecithin-cholesterol acyltransferase in hypercholesterolemia.

C Napoli1, M Leccese, G Palumbo, F de Nigris, P Chiariello, P Zuliani, P Somma, M Di Loreto, C De Matteis, F Cacciatore, P Abete, A Liguori, M Chiariello, F P D'Armiento.   

Abstract

BACKGROUND: The enzyme lecithin-cholesterol acyl transferase (LCAT) esterifies free cholesterol on high-density lipoprotein (HDL) and the cholesteryl ester transfer protein (CETP) transfers cholesteryl ester to very-low-density lipoprotein (VLDL) and low-density lipoproteins (LDL). Using statins, contradictory findings have been made regarding CETP activity in normolipidemic individuals and in those with familial dysbetalipoproteinemia. In contrast, LCAT activity appears to be unaffected by simvastatin. Antioxidants have also been proposed for the use of anti-atherosclerotic treatment, because the oxidation of LDL may have a key role in the pathophysiology of atherogenesis.
OBJECTIVE: To investigate, in hypercholesterolemic patients, whether a combination of pravastatin with the antioxidant, vitamin E, has greater effects on the activity of CETP and of LCAT than does pravastatin alone.
METHODS: This placebo-diet-controlled multicenter trial included 220 hypercholesterolemic patients who were assigned randomly to groups to receive: diet and 20-40 mg pravastatin (n = 52), diet and alpha-tocopherol (n = 60), or diet associated with placebo (n = 52). Plasma LCAT activity was determined using excess exogenous substrate, containing [3H]cholesterol. Plasma CETP activity was measured in the supernatant fraction after precipitation of endogenous apo B-containing lipoproteins with phosphotungstate-Mg2+. The exchange of cholesteryl esters between [14C]cholesteryl ester-labeled LDL and unlabeled HDL was measured during a 16-h incubation, while LCAT was inhibited.
RESULTS: The addition of pravastatin to the diet induced a significant decrease in plasma CETP activity (P < 0.05); this effect was less evident in the group cotreated with vitamin E. For the first time, it was shown that CETP concentrations increased significantly after vitamin E alone (P < 0.05). No significant differences in the plasma activity of LCAT were observed among the groups.
CONCLUSIONS: Pravastatin reduced CETP activity, but not that of LCAT. Addition of vitamin E prevented the decrease in CETP activity and had no effect on LCAT activity. The mechanism responsible for these effects is unknown, but could involve the prevention of radical-induced damage to CETP by vitamin E.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9710685     DOI: 10.1097/00019501-199809050-00003

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  3 in total

Review 1.  Pravastatin: a review of its use in elderly patients.

Authors:  Lynne M Bang; Karen L Goa
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 2.  Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia.

Authors:  Anita Malhotra; Nusrat Shafiq; Anjuman Arora; Meenu Singh; Rajendra Kumar; Samir Malhotra
Journal:  Cochrane Database Syst Rev       Date:  2014-06-10

Review 3.  Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic review.

Authors:  Salmaan Kanji; Dugald Seely; Fatemeh Yazdi; Jennifer Tetzlaff; Kavita Singh; Alexander Tsertsvadze; Andrea C Tricco; Margaret E Sears; Teik C Ooi; Michele A Turek; Becky Skidmore; Mohammed T Ansari
Journal:  Syst Rev       Date:  2012-05-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.